描述 |
Cefoperazone是头孢菌素类抗生素。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
在DMSO中10mM
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC([C@H](NC(N4C(C(N(CC)CC4)=O)=O)=O)C5=CC=C(O)C=C5)=O)C1=O)O |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
嘌呤霉素盐酸盐 | G-418 硫酸盐 | 衣霉素 | 潮霉素B | 盐霉素 | 阿维巴坦钠 | 硫酸新霉素 | 法硼巴坦 | 甲氧西林钠 | 利福平 | 甲硝唑 | 羧苄青霉素钠 | 头孢他啶 | Eravacycline dihydrochloride | 头孢噻肟钠 |
密度 | 1.8±0.1 g/cm3 |
---|---|
熔点 | 169-171?C |
分子式 | C25H27N9O8S2 |
分子量 | 645.667 |
精确质量 | 645.142395 |
PSA | 270.86000 |
LogP | 1.43 |
外观性状 | 白色结晶粉末 |
折射率 | 1.819 |
储存条件 | 0-10°C;避免加热 |
稳定性 |
在PH=4.0~7.0时稳定,碱性时不稳定。 |
分子结构 |
1、 摩尔折射率:158.18 2、 摩尔体积(cm3/mol):363.6 3、 等张比容(90.2K):1110.2 4、 表面张力(dyne/cm):86.8 5、 极化率(10-24cm3):62.70 |
更多 |
1.性状:白色或类白色结晶性粉末,无臭,味微苦。 2.溶解性:有引湿性。溶于丙酮或二甲亚砜,微溶于甲醇或乙醇,极微溶于水。 |
以7-ACA为原料,先与5-巯基-1-甲基-四氮唑反应生成3位取代的7-ATCA中间体,然后和α-(对羟基苯基)-α-[(4-乙基-2,3-二氧代-1-吡嗪基)甲酰胺基]乙酰氯缩合,经酸化调节Ph值使成头孢哌酮游离酸结晶,用碳酸氢钠溶解,可得头孢哌酮的钠盐。
海关编码 | 2941905600 |
---|
CEFOPERAZONE ACID |
Cefoperazone |
acide (6R,7R)-7-{[(2R)-2-{[(4-éthyl-2,3-dioxopipérazin-1-yl)carbonyl]amino}-2-(4-hydroxyphényl)acétyl]amino}-3-{[(1-méthyl-1H-tétrazol-5-yl)sulfanyl]méthyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2 |
(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid dihydrate |
Cefobis |
EINECS 263-749-4 |
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo- |
Cefoperazone dihydrate |
Prestwick_735 |
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)- |
HMS1569A15 |
(6R,7R)-7-{[(2R)-2-{[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
HMS2096A15 |
Cefob |
CP 52640-2 |
l~rdum |
CEFOBID |
Cephaperazon |
Medocef |
7-[D-(-)-a-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)-a-(4-hydroxyphenyl)acetamido]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-3-cephem-4-carboxylic Acid |
MFCD00865067 |
(6R,7R)-7-{[(2R)-2-{[(4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
(6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
(6R,7R)-7-{[(2R)-2-{[(4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carbon |
cefoperazine |